News
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 (see chart 2). Lilly’s edge rests on a more effective drug, better execution, keener pricing and a stronger pipeline.
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...
(Reuters) -A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight ...
7hon MSN
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
Adweek on MSN19h
Eli Lilly's Big Task: Become a Loved and Trusted Pharma BrandA new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback